Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cocaine esterase - Tonix Pharmaceuticals Holding Corp

Next Previous
X
Search
Drug Profile

Cocaine esterase - Tonix Pharmaceuticals Holding Corp

Alternative Names: Cocaine esterase; RBP 8000; T172R/G173G cocaine esterase; T172R/G173Q double-mutant cocaine esterase; TNX 1300

Latest Information Update: 15 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University; University of Kentucky; University of Michigan
  • Developer Indivior
  • Class Antidotes; Carboxylic ester hydrolases; Drug withdrawal therapies
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cocaine-related disorders

Most Recent Events

  • 27 Jun 2024 Tonix Pharmaceuticals initiates a phase II CATALYST trial for Cocaine-related disorders in USA (IV, infusion) (NCT06045793)
  • 01 Apr 2024 Tonix Pharmaceuticals plans a phase II trial for Cocaine-related disorders in the US in the second quarter of 2024
  • 13 Mar 2023 Tonix Pharmaceuticals has patent protection for Cocaine esterase in Canada, New Zealand, Europe – (Germany, Spain, France, United Kingdom, and Italy), South Africa, Mexico and Israel

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top